About the Authors
- Nada M. S. Al-Saffar
-
* E-mail: Nada.Al-Saffar@icr.ac.uk
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Alice Agliano
-
Contributed equally to this work with: Alice Agliano, Lynley V. Marshall
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Lynley V. Marshall
-
Contributed equally to this work with: Alice Agliano, Lynley V. Marshall
Affiliations Divisions of Cancer Therapeutics and Molecular Pathology, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom, Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- L. Elizabeth Jackson
-
Current address: Retired.
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Geetha Balarajah
-
Current address: The Centre for Molecular Pathology, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Jasmin Sidhu
-
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Paul A. Clarke
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
- Chris Jones
-
Affiliation Divisions of Cancer Therapeutics and Molecular Pathology, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Paul Workman
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
- Andrew D. J. Pearson
-
Current address: Retired.
Affiliation Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Martin O. Leach
-
Affiliation Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Competing Interests
N.M.S.A, A.A, L.E.J, G.B, J.S, P.A.C, C.J, A.D.J.P, P.W and M.O.L are employees of The Institute of Cancer Research, which has a commercial interest in the development of PI3K inhibitors, and operates a Rewards to Inventors scheme. P.W and P.A.C have been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma and intellectual property arising from the program has been licensed to Genentech. Genentech and Piramed Pharma were acquired by Roche. P.W was a founder of, consultant to, and Scientific Advisory Board member of Piramed Pharma (acquired by Roche); was a founder of, consultant to and Scientific Advisory Board and Main Board member of Chroma Therapeutics; is a Consultant/ Scientific Advisory Board member to Nextech Ventures, Astex Pharmaceuticals and Wilex Oncology; and was formerly an employee of AstraZeneca. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: NMSA LVM. Data curation: NMSA. Formal analysis: NMSA AA LVM. Funding acquisition: NMSA LVM MOL CJ. Investigation: NMSA AA LVM LEJ GB JS. Methodology: NMSA AA LVM PAC CJ. Project administration: NMSA. Resources: NMSA LVM MOL CJ ADJP. Supervision: NMSA MOL CJ ADJP PAC PW. Validation: NMSA AA. Visualization: NMSA AA. Writing – original draft: NMSA. Writing – review & editing: NMSA AA LVM LEJ GB JS MOL CJ ADJP PAC PW.